文献速递腹部MR

第4周MRI肝脏脂肪减少可早期预测非酒精性脂肪性肝炎的治疗反应

Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
PubMed 文献 · Radiology · 2021-06-01

本研究为前瞻性Ib期临床试验的二次分析,共48例非酒精性脂肪性肝炎参与者,分别接受MET409或安慰剂治疗,分析基线、4周和12周MRI质子密度脂肪分数(PDFF)。第4周PDFF相对变化和血清碱性磷酸酶水平可预测第12周PDFF相对变化;第4周PDFF相对减少≥19.3%预测第12周PDFF相对减少≥30%的AUC为0.98(敏感度89%,特异度95%)。

要点

  • 第4周PDFF相对减少≥19.3%可高度预测第12周PDFF相对减少≥30%(AUC 0.98)。
  • 第4周PDFF相对变化和血清ALP水平是第12周PDFF相对变化的预测因子。
  • 在预测模型中加入ALP并未改善模型性能。

核心结论

  • 在非酒精性脂肪性肝炎Ib期治疗试验参与者中,第4周MRI质子密度脂肪分数(PDFF)相对变化对第12周MRI PDFF评估的治疗反应具有高度预测价值。

研究设计与样本

  • 前瞻性Ib期临床试验的二次分析,纳入48例非酒精性脂肪性肝炎参与者(中位年龄57岁,年龄范围40-62岁,32例女性),其中30例接受MET409治疗、18例接受安慰剂治疗,于基线及第4周、第12周行MRI PDFF评估,分析时间为2019年6月至2020年1月。

诊断标准与关键数值

  • 第4周PDFF相对减少≥19.3%预测第12周PDFF相对减少≥30%的AUC为0.98(敏感度89%,特异度95%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Pharmacologic treatment of nonalcoholic steatohepatitis (NASH) is long term in nature; thus, early noninvasive treatment response assessment is important for therapeutic decision making. Purpose To investigate potential early predictors of the 12-week treatment response estimated by using the MRI-based proton-density fat fraction (PDFF). Materials and Methods In this secondary analysis of a prospective phase Ib clinical trial evaluating a candidate treatment (MET409, a farnesoid X receptor agonist) for NASH, participants were analyzed at baseline and at 4 and 12 weeks after either active treatment with MET409 or placebo treatment between June 2019 and January 2020. Correlation and multiple linear regression analyses were used to identify clinical, laboratory, and imaging predictors of the relative PDFF change at week 12 (W12). Multivariate logistic regression analysis was used to develop predictive models for an at least 30% relative PDFF reduction at W12, a well-validated indicator of histologic improvement. Model performance was characterized by using area under the receiver operating characteristic curve (AUC) analysis, sensitivity, and specificity. Results A total of 48 participants were analyzed (median age, 57 years; age range, 40-62 years; 32 women), among whom 30 received MET409 and 18 received a placebo. The week 4 (W4) relative changes in PDFF (regression coefficient = 1.24, P < .001) and the serum alkaline phosphatase (ALP) level (regression coefficient = -0.29, P = .03) were predictors of the W12 relative PDFF change. An at least 19.3% relative PDFF reduction at W4 yielded an AUC of 0.98 (sensitivity, 89%; specificity, 95%) for predicting an at least 30% relative PDFF reduction at W12. The addition of ALP to the predictive model did not improve model performance. Conclusion In participants with nonalcoholic steatohepatitis enrolled in a phase Ib treatment trial, the relative change in the MRI-based proton-density fat fraction (PDFF) at week 4 was highly predictive of the treatment response estimated by using the week 12 MRI-based PDFF. © RSNA, 2021 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Jiang H, Chen HC, Lafata KJ, et al. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis. Radiology. 2021. PMID: 34060937. doi:10.1148/radiol.2021204325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。